Medicare Advantage reimbursement alerts

The CMS is seeking public comment on information collection activities that may influence Medicare billing and reimbursement processes. Stakeholder feedback could lead to changes that impact billing p

The proposed information collection by CMS is crucial for evaluating the efficiency and effectiveness of various Medicare services. This initiative might impact billing practices as the agency gathers

The request for information on Medicare Advantage data aims to enhance CMS's data capabilities, which could lead to changes in billing practices and reimbursement rates for Medicare Advantage plans. I

The finalized changes to Medicare Advantage provider directories may impact billing by improving transparency in provider availability, which could lead to better patient access and, potentially, incr

The recent rule aims to enhance the integrity and accuracy of payments in the Medicare Advantage program by outlining a revised audit methodology for the Risk Adjustment Data Validation (RADV). By cod

The proposed rule aims to enhance the electronic exchange of health care data and streamline prior authorization processes, which can significantly improve billing efficiency for Medicare Advantage or

The recent rule changes for Medicare Advantage are expected to enhance the overall efficiency of billing and reimbursement processes, particularly in star ratings and drug coverage, which could impact

The proposed rule is affecting payment parameters and risk adjustment mechanisms within the Patient Protection and Affordable Care Act. These changes may influence reimbursement rates and complia

The GUARD Model aims to reassess the payment method for Part D drug inflation rebates, potentially impacting reimbursement rates and overall drug costs for Medicare enrollees. By exploring alternative

The proposed GLOBE model aims to introduce a new payment structure for Part B drugs, potentially lowering costs for Medicare FFS beneficiaries and the program overall. This shift may impact reimbursem

The proposed rule introduces significant changes to the Medicare Advantage program, aiming to enhance the overall patient experience and streamline processes. These changes could potentially impact bi

The new final rule introduces significant changes to the Medicare Advantage and drug benefit programs which will affect both billing and reimbursement processes. Providers must be aware of updates reg

The proposed information collection by CMS aims to enhance the efficiency and transparency of the billing and reimbursement process. By allowing public comments, it seeks to refine data collection pra

The proposed rule for the Medicare Advantage program introduces significant changes that could impact billing and reimbursement processes. Changes to Star Ratings and drug coverage may influence provi

The changes to the Medicare Advantage and Prescription Drug Benefit programs are expected to supports compliance with updated rates processes and improve care coordination. These updates focus on Star Ratings and heal

The announcement encourages public comments on CMS's information collection plans, which may impact billing practices by affecting data collection requirements. This could influence how providers subm

The upcoming final rule aims to enhance the electronic exchange of healthcare data and streamline prior authorization processes, which is expected to improve efficiency in billing practices. These cha

The proposed rule outlines critical updates to payment parameters for 2025, impacting reimbursement structures for Qualified Health Plans. These changes could affect billing practices and coding due t

The proposed rule for Contract Year 2025 introduces significant changes to Medicare Advantage and prescription drug programs, which could impact billing and reimbursement processes. Adjustments in are

The recent updates to the Medicare Advantage program impact billing and reimbursement by enhancing the focus on health equity, prior authorization processes, and network adequacy, which may affect cla

The Food and Drug Administration (FDA) is classifying the von Willebrand factor assay into class II (special controls). The special controls that apply to the d

This proposed rule describes alternatives to modify the limit on the total payment rate and other requirements for State directed payments in Medicaid managed c

Managed Care

This final rule revises the Medicare Advantage (Part C), Medicare Prescription Drug Benefit (Part D), and Medicare cost plan regulations to implement changes re

These proposals are intended to improve the electronic exchange of health care data and streamline processes related to prior authorization by increasing the in

This request for information (RFI) solicits stakeholder feedback on potential regulatory changes that might be included in a potential upcoming CRUSH proposed r